Skip to contentT
TELA Bio, Inc.
T
TELATELA Bio, Inc. Q2 2025 · 10-Q
Revenue$20.20M$20.20M+25.5% vs Q2 2024 Net Income-$9.92M-$9.92MN/M vs Q2 2024 EPS Diluted-$0.22-$0.22N/M vs Q2 2024 Gross Profit$14,105,000+27.4% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
TELA Bio, Inc. · CIK 1561921 · Engraved from SEC EDGAR
Operating Cash Flowderived-$7,905,000N/M Free Cash Flowderived-$8,019,000N/M Margins · derivedGross margin69.8%+1.0 pt vs Q2 2024
Operating margin-45.0%+26.9 pt vs Q2 2024
Net margin-49.1%+29.2 pt vs Q2 2024
ended Jun 30, 2025 · filed Aug 11, 2025 · 42 d after period end